EPO and proliferative diabetic retinopathy: One promising discovery, supported by robust statistical and functional evidence, links EPO (erythropoietin) promoter polymorphism to both the presence of proliferative diabetic retinopathy (PDR) and ESRD, as well as EPO expression [109].